Which biologic agents are recommended for patients with moderate-to-severe asthma uncontrolled on high-dose inhaled corticosteroid/long-acting β2-agonist therapy, based on allergic, eosinophilic, or type‑2 inflammatory phenotypes?

Biologic Therapy Selection in Moderate-to-Severe Asthma

For patients with moderate-to-severe asthma uncontrolled on high-dose ICS/LABA, select biologics based on phenotype: dupilumab for type 2 asthma with elevated FeNO, anti-IL-5/5R agents (mepolizumab, benralizumab, reslizumab) for eosinophilic asthma, omalizumab for allergic asthma with elevated IgE, and tezepelumab for non-type 2 or mixed phenotypes.

Phenotype-Driven Selection Algorithm

Allergic Asthma (IgE-mediated)

• Omalizumab is the biologic of choice when serum IgE >30 IU/mL and documented allergen sensitivity 1
• Particularly effective in allergy-driven disease 2
• Reduces exacerbations by approximately 25% 3
• First-line choice for women planning pregnancy 2

Eosinophilic Asthma

Select based on blood eosinophil thresholds:

• Mepolizumab: Blood eosinophils ≥150 cells/µL 1

  • Reduces exacerbations by ~50% 3
  • Preferred when CRSwNP coexists with highly eosinophilic asthma 2

• Reslizumab: Blood eosinophils ≥400 cells/µL 1

  • Also achieves ~50% exacerbation reduction 3

• Benralizumab: Blood eosinophils ≥300 cells/µL 1

  • Anti-IL-5 receptor alpha mechanism
  • ~50% exacerbation reduction 3

Type 2 High Asthma (Elevated FeNO)

• Dupilumab is the optimal choice for FeNO-high endotypes 3
  • Anti-IL-4 receptor alpha mechanism
  • Reduces exacerbations by 47% 3
  • Recommended for severe uncontrolled allergic and eosinophilic asthma 1
  • First choice when CRSwNP is present 2
  • Effective in corticosteroid-dependent asthma 1

Non-Type 2 or Mixed Phenotypes

• Tezepelumab for type 2/non-type 2 asthma 2
  • Anti-TSLP mechanism
  • Broadest indication when phenotype is unclear or mixed

Key Comorbidity Considerations

When comorbidities are present, they should guide biologic selection 4:

• CRSwNP: Dupilumab first-line 2; mepolizumab if highly eosinophilic asthma coexists 2
• Atopic dermatitis: Dupilumab
• Chronic spontaneous urticaria: Omalizumab
• Eosinophilic COPD: Dupilumab 2
• Pregnancy planning: Omalizumab 2
• EGPA or eosinophilic esophagitis: Consider anti-IL-5/5R agents

Biomarker Thresholds Summary

Biologic	Primary Target	Key Biomarker	Threshold
Omalizumab	IgE	Serum IgE	>30 IU/mL
Mepolizumab	IL-5	Blood eosinophils	≥150 cells/µL
Reslizumab	IL-5	Blood eosinophils	≥400 cells/µL
Benralizumab	IL-5Rα	Blood eosinophils	≥300 cells/µL
Dupilumab	IL-4Rα	FeNO/eosinophils	Elevated FeNO
Tezepelumab	TSLP	None required	Any phenotype

Critical Implementation Points

Administration: First 2 injections should occur in hospital for training and monitoring for anaphylaxis risk (particularly with omalizumab 5), then self-injection is possible 2. Onset of effect typically occurs within weeks to months 2.

When phenotype is unclear: T2-high asthma is five times more common than T2-low 6. In the absence of clear biomarkers, tezepelumab provides the broadest coverage across phenotypes 2.

Switching biologics: If suboptimal control persists after 3-6 months, switching is supported by evidence showing significant improvements in exacerbations, asthma control (ACT improvement of 5.18 points), and lung function (FEV1 improvement of 0.18L) 7. The most common switching patterns are mepolizumab-to-benralizumab and omalizumab-to-anti-IL-5 agents 7.

Common Pitfalls to Avoid

• Do not use anti-IL-5/5R agents when eosinophils are below threshold—efficacy is biomarker-dependent
• Do not overlook comorbidities that could be treated simultaneously with one biologic (e.g., dupilumab for asthma + CRSwNP + atopic dermatitis)
• Do not continue a biologic beyond 4-6 months without reassessing clinical response across multiple domains (exacerbations, symptoms, lung function, OCS use)
• Ensure patients understand chronicity requires optimal adherence and trigger avoidance 2